Soltis Investment Advisors LLC Has $3.22 Million Stake in Kenvue Inc. (NYSE:KVUE)

Soltis Investment Advisors LLC lowered its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,709 shares of the company’s stock after selling 1,149 shares during the period. Soltis Investment Advisors LLC’s holdings in Kenvue were worth $3,218,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Grove Bank & Trust lifted its holdings in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue in the fourth quarter worth about $29,000. Riverview Trust Co bought a new position in Kenvue during the third quarter worth about $30,000. Fortitude Family Office LLC boosted its holdings in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Kenvue in the 3rd quarter valued at approximately $35,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE stock opened at $20.23 on Monday. The company has a 50 day moving average price of $21.54 and a 200 day moving average price of $21.97. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $38.79 billion, a PE ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

Several research firms recently commented on KVUE. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Canaccord Genuity Group reduced their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Bank of America upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.